Trillium Asset Management LLC lowered its position in Shire PLC (NASDAQ:SHPG) by 62.1% during the second quarter, Holdings Channel reports. The institutional investor owned 20,007 shares of the biopharmaceutical company’s stock after selling 32,750 shares during the period. Trillium Asset Management LLC’s holdings in Shire PLC were worth $3,683,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the company. UBS Asset Management Americas Inc. increased its stake in shares of Shire PLC by 796.2% in the first quarter. UBS Asset Management Americas Inc. now owns 290,929 shares of the biopharmaceutical company’s stock worth $50,011,000 after buying an additional 258,466 shares in the last quarter. UBS Group AG increased its stake in shares of Shire PLC by 1,825.2% in the first quarter. UBS Group AG now owns 1,227,631 shares of the biopharmaceutical company’s stock worth $211,030,000 after buying an additional 1,163,865 shares in the last quarter. Lazard Asset Management LLC increased its stake in shares of Shire PLC by 8.3% in the first quarter. Lazard Asset Management LLC now owns 604,947 shares of the biopharmaceutical company’s stock worth $103,989,000 after buying an additional 46,519 shares in the last quarter. State Street Corp purchased a new stake in shares of Shire PLC during the first quarter worth about $3,362,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Shire PLC by 5.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,728 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 82 shares in the last quarter. Institutional investors and hedge funds own 24.26% of the company’s stock.
Shares of Shire PLC (NASDAQ:SHPG) traded up 0.49% during midday trading on Friday, reaching $194.50. 615,786 shares of the company were exchanged. The stock’s 50-day moving average price is $195.68 and its 200-day moving average price is $186.83. The company has a market capitalization of $57.93 billion, a PE ratio of 40.42 and a beta of 1.16. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.35. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. Shire PLC’s revenue was up 55.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.63 earnings per share. Analysts anticipate that Shire PLC will post $12.92 EPS for the current year.
The business also recently declared a dividend, which will be paid on Friday, October 7th. Shareholders of record on Friday, September 9th will be paid a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.
Several research firms recently weighed in on SHPG. Jefferies Group reiterated a “buy” rating and issued a $262.00 target price on shares of Shire PLC in a report on Tuesday, September 20th. HSBC downgraded shares of Shire PLC from a “buy” rating to a “hold” rating in a report on Monday, September 26th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire PLC in a report on Monday, September 26th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Finally, Guggenheim reiterated a “neutral” rating on shares of Shire PLC in a report on Wednesday, August 3rd. Five investment analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $232.75.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.